Table 10.
Characteristics of included studies and their reports for ertugliflozin
| Author | Title | Journal | Methods | Findings |
|---|---|---|---|---|
|
Cannon et al. (2020) (VERTIS‐CV Trial) |
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes | The New England Journal of Medicine | 8246 T2DM patients with established ASCVD underwent randomization to ertugliflozin or placebo, followed for a mean of 3.5 years. | With regard to MACE, ertugliflozin was non‐inferior to placebo among type 2 diabetic patients with ASCVD. |
| Reports from VERTIS‐CV | ||||
| Dagogo‐Jack et al. (2022) | Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose‐lowering agent: An analysis from VERTIS CV | Diabetes, Obesity and Metabolism | In this analysis from VERTIS‐CV trial, time to the first event of CV death, MI, or stroke (MACE), and other CV outcomes were assessed. | Ertugliflozin's effects on cardiorenal outcomes were consistent across patient subgroups stratified by baseline glucose‐lowering agent. The extent of HbA1c, body weight, SBP, eGFR, and UACR reductions with ertugliflozin did not differ significantly by baseline glucose‐lowering drug class. |
| Cherney et al. (2021) | Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomized VERTIS CV trial | Diabetologia | In VERTIS‐CV participants, who were randomized to receive ertugliflozin or matching placebo, added on to existing treatment, doubling of serum creatinine was replaced with sustained 40% decrease from baseline eGFR, and the effect on UACR and eGFR were assessed. | Ertugliflozin, when administered in addition to standard‐of‐care drugs, was related to a lower chance of a sustained 40% reduction in eGFR, reduced albuminuria, and eGFR preservation over time in patients with T2DM and established ASCVD. |
| Cosentino et al. (2020) | Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease Results of the VERTIS CV Trial | Circulation | Patients from VERTIS‐CV trial, both with LVEF ≤45% and LVEF >45%, were randomly assigned to ertugliflozin or placebo. Primary outcome assessed was the time to first MACE. |
Ertugliflozin reduced total events of HHF/CV death by 17% and total HHF events by 30%. Ertugliflozin reduced the incidence of first and total HHF, as well as total HHF/CV death, in individuals with T2DM, providing additional support for the use of SGLT2 inhibitors in the primary and secondary prevention of HHF. |
ASCVD, atherosclerotic cardiovascular disease; CV, cardiovascular; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; HHF, hospitalization for heart failure; LVEF, left ventricular ejection fraction; MACE, major adverse cardiovascular events; MI, myocardial infarction; SBP, systolic blood pressure; SGLT2, sodium‐glucose cotransporter 2; T2DM, type 2 diabetes mellitus; UACR, urinary albumin‐to‐creatinine ratio.